To determine the signaling pathways through which RBBP9 loss enhances intestinal inflammation and inflammation-mediated proliferation, we focused on the overlapping gene signatures between the RNA-seq data from the AOM/DSS and ApcMin/+ tumor models (Figure 6D). This evidence concerns the gene RBBP9 and neoplasm.